Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved for second-line treatment in combination with docetaxel. This review provides a summary of pivotal trials with anti-angiogenic drugs in NSCLC in different settings. We give an overview of how to position anti-angiogenic therapy in the current treatment algorithms and highlight future directions. The identification of predictive biomarkers for patient selection could improve the success of anti-angiogenic drugs and represents an important area of research. In addition, novel therapeutic targets including endothelial metabolomic intermediates and cellular components of the tumor microenvironment could lead to the identification of innovative new targets besides the VEGF axis.

Journal Section:
Review Article
Keywords:
Anti-angiogenesis, Disease management, Non-small cell lung cancer, NSCLC
1.
Reck M, Rabe KF: Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 2017;377:849-861.
2.
Reinmuth N, Reck M: Immunotherapy for lung cancer. Oncol Res Treat 2016;39:360-368.
3.
Reck M, Rodriguez-Abreu D, Robinson AG, et al.; KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-1833.
4.
Welti J, Loges S, Dimmeler S, Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123:3190-3200.
5.
Loges S, Mazzone M, Hohensinner P, Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167-170.
6.
Sandler A, Gray R, Perry MC, et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
7.
Reck M, von Pawel J, Zatloukal P, et al.; BO17704 Study Group: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-1809.
8.
Ardizzoni A, Boni L, Tiseo M, et al.; CISCA (CISplatin versus CArboplatin) Meta-analysis Group: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
9.
Ellis PM: Anti-angiogenesis in personalized therapy of lung cancer; in Ahmad A, Gadgeel S (eds): Lung Cancer and Personalized Medicine: Current Knowledge and Therapies. Cham, Springer International Publishing, 2016, pp. 91-126.
10.
Chu BF, Otterson GA: Incorporation of antiangiogenic therapy into the non-small-cell lung cancer paradigm. Clin Lung Cancer 2016;17:493-506.
11.
Ramalingam SS, Dahlberg SE, Langer CJ, et al.; Eastern Cooperative Oncology Group: Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
12.
Laskin J, Crino L, Felip E, et al.: Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 2012;7:203-211.
13.
Zhu J, Sharma DB, Gray SW, et al.: Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012;307:1593-1601.
14.
Schuette W, Schneider CP, Engel-Riedel W, et al.: 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer. Lung Cancer (Auckl) 2017;8:217-229.
15.
Paz-Ares LG, de Marinis F, Dediu M, et al.: PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-2902.
16.
Barlesi F, Scherpereel A, Gorbunova V, et al.: Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014;25:1044-1052.
17.
Zinner RG, Obasaju CK, Spigel DR, et al.: PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015;10:134-142.
18.
Patel JD, Socinski MA, Garon EB, et al.: PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:4349-4357.
19.
Wakelee HA, Dahlberg SE, Keller SM, et al.; ECOG-ACRIN: Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2017;18:1610-1623.
20.
De Gramont A, Van Cutsem E, Schmoll HJ, et al.: Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225-1233.
21.
Bell R, Brown J, Parmar M, et al.: Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol 2017;28:754-760.
22.
Chaft JE, Rusch V, Ginsberg MS, et al.: Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol 2013;8:1084-1090.
23.
Garon EB, Ciuleanu TE, Arrieta O, et al.: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-673.
24.
Lee S, Chen TT, Barber CL, et al.: Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703.
25.
Doebele RC, Spigel D, Tehfe M, et al.: Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 2015;121:883-892.
26.
Manzo A, Montanino A, Carillio G, et al.: Angiogenesis inhibitors in NSCLC. Int J Mol Sci 2017;18.
27.
Reck M, Kaiser R, Mellemgaard A, et al.; LUME-Lung 1 Study Group: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-155.
28.
Hanna NH, Kaiser R, Sullivan RN, et al.; LUME-Lung 2 Study Group: Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer 2016;102:65-73.
29.
Baggstrom MQ, Socinski MA, Wang XF, et al.: Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance). J Thorac Oncol 2017;12:843-849.
30.
Kubota K, Yoshioka H, Oshita F, et al.: Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in East Asian patients with advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2017;35:3662-3670.
31.
Duignan IJ, Corcoran E, Pennello A, et al.: Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia 2011;13:49-59.
32.
Seto T, Kato T, Nishio M, et al.: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014;15:1236-1244.
33.
Rosell R, Dafni U, Felip E, et al.; BELIEF collaborative group: Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017;5:435-444.
34.
Ichihara E, Hotta K, Nogami N, et al.: Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol 2015;10:486-491.
35.
Ninomiya T, Nogami N, Kozuki T, et al.: A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Lung Cancer 2018;115:103-108.
36.
Tabernero J: The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007;5:203-220.
37.
Reck M, Garon EB, Paz-Ares L, et al.: Randomized, double-blind phase Ib/III study of erlotinib with ramucirumab or placebo in previously untreated EGFR-mutant metastatic non-small-cell lung cancer (RELAY): phase Ib results. Clin Lung Cancer 2017; Epub ahead of print.
38.
Paz-Ares L, Hirsh V, Zhang L, et al.: Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial: a phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol 2015;10:1745-1753.
39.
Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ: EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. Ann Oncol 2014;25:1941-1948.
40.
Motz GT, Coukos G: The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011;11:702-711.
41.
Reck M, Socinski MA, Cappuzzo F, et al.: Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150); in Andre F (ed): ESMO Immuno-Oncology Congress 2017. Geneva, Oxford University Press, 2017.
42.
Borghaei H, Paz-Ares L, Horn L, et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-1639.
43.
Brahmer J, Reckamp KL, Baas P, et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
44.
Herbst RS, Baas P, Kim DW, et al.: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-1550.
45.
Rittmeyer A, Barlesi F, Waterkamp D, et al.; OAK Study Group: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-265.
46.
Horn L, Spigel DR, Vokes EE, et al.: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35:3924-3933.
47.
Reck M, Paz-Ares L, Bidoli P, et al.: Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer 2017;112:181-187.
48.
Gaschler-Markefski B, Sikken P, Heymach JV, et al.: Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. ESMO Open 2017;2:e000102.
49.
Gottfried M, Bennouna J, Bondarenko I, et al.: Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-Lung 1 study. Target Oncol 2017;12:475-485.
50.
Popat S, Mellemgaard A, Reck M, Hastedt C, Griebsch I: Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future Oncol 2017;13:1159-1171.
51.
Perol M, Ciuleanu TE, Arrieta O, et al.: Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer 2016;93:95-103.
52.
Novello S, Kaiser R, Mellemgaard A, et al.; LUME-Lung 1 Study Group: Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer 2015;51:317-326.
53.
Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ: Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013;31:1219-1230.
54.
Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412.
55.
Miles D, Cameron D, Bondarenko I, et al.: Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer 2017;70:146-155.
56.
Potente M, Carmeliet P: The link between angiogenesis and endothelial metabolism. Annu Rev Physiol 2017;79:43-66.
57.
Zecchin A, Kalucka J, Dubois C, Carmeliet P: How endothelial cells adapt their metabolism to form vessels in tumors. Front Immunol 2017;8:1750.
58.
Wroblewski M, Bauer R, Cubas Cordova M, et al.: Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. Nat Commun 2017;8:269.
© 2018 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.